OneMedNet Corporation (NASDAQ:ONMD – Get Free Report) Director Thomas Kosasa acquired 129,758 shares of the business’s stock in a transaction that occurred on Wednesday, October 7th. The stock was bought at an average cost of $5.78 per share, for a total transaction of $750,001.24. Following the completion of the purchase, the director owned 1,983,573 shares of the company’s stock, valued at $11,465,051.94. This trade represents a 7.00% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.
Thomas Kosasa also recently made the following trade(s):
- On Thursday, July 30th, Thomas Kosasa bought 144,927 shares of OneMedNet stock. The stock was bought at an average price of $6.90 per share, for a total transaction of $999,996.30.
OneMedNet Price Performance
NASDAQ:ONMD opened at $4.75 on Friday. The company has a 50 day simple moving average of $6.03 and a two-hundred day simple moving average of $7.19. OneMedNet Corporation has a fifty-two week low of $3.61 and a fifty-two week high of $28.20.
Analyst Ratings Changes
View Our Latest Report on ONMD
About OneMedNet
OneMedNet Corporation is a healthcare technology company that develops infrastructure for accessing, managing and analyzing medical data. Its platform is designed to help healthcare providers, researchers, life sciences companies and other authorized users work with clinical and medical-imaging information while keeping the underlying data within the organization that controls it.
The company’s technology uses a federated data model, allowing participating institutions to collaborate on data analysis without routinely transferring sensitive patient information to a centralized repository.
Featured Stories
- Five stocks we like better than OneMedNet
- ASML Can’t Keep Up With AI Demand—Why That’s a Good Thing
- Enovix’s 100,000-Battery Drone Order Sets Up a Test of Its Production Plans
- AMD’s Support Could Help Fermi Stock Overcome Its Biggest Hurdle
- Beyond the GPU: Credo Paves the Next AI Data Superhighway
Receive News & Ratings for OneMedNet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OneMedNet and related companies with MarketBeat.com's FREE daily email newsletter.
